Estados financieros detallados de Harvard Bioscience, Inc. (HBIO): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Harvard Bioscience, Inc. registró ingresos de $86.5M en el último ejercicio fiscal, con un CAGR de 5 años del -3.3%.
Márgenes de los últimos 12 meses: margen bruto 58.2%, margen operativo 1.2%, margen neto -11.9%. El flujo de caja libre creció a un CAGR del -7.2% en 5 años.
Al precio actual de $7.97, HBIO presenta beneficios negativos (P/E no significativo) y un ROE del -92.01%. La capitalización bursátil es de $36M.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $104.5M | $101.9M | $120.8M | $116.2M | $102.1M | $118.9M | $113.3M | $112.2M | $94.1M | $86.5M |
| Coste de Ventas | $56.1M | $54.3M | $57.6M | $51.9M | $44.1M | $51.3M | $52.5M | $46.2M | $39.4M | $40.7M |
| Beneficio Bruto | $48.4M | $47.6M | $63.2M | $64.3M | $58.0M | $67.7M | $60.8M | $66.1M | $54.8M | $45.9M |
| I+D | $5.4M | $5.6M | $11.0M | $10.7M | $8.7M | $10.8M | $12.3M | $11.8M | $10.4M | $8.8M |
| Generales y Administrativos | $41.4M | $39.6M | $45.8M | $46.0M | $43.4M | $48.9M | $49.5M | $46.9M | $43.7M | $37.0M |
| Gastos Operativos | $49.5M | $47.7M | $62.2M | $63.9M | $57.8M | $65.6M | $67.8M | $64.2M | $61.0M | $46.5M |
| Beneficio Operativo | -$3.0M | -$101000 | $984000 | $377000 | $221000 | $2.1M | -$6.9M | $1.9M | -$6.2M | -$629000 |
| EBITDA | $1.8M | -$101000 | $5.4M | $7.6M | $5.2M | $9.0M | $944000 | $8.0M | -$1.5M | -$46.5M |
| Gastos por Intereses | $642000 | $713000 | $5.4M | $5.4M | $4.8M | $1.5M | $2.5M | $3.6M | $3.2M | $4.9M |
| Beneficio Antes de Impuestos | -$3.1M | -$2.1M | -$8.5M | -$5.5M | -$7.3M | -$140000 | -$9.2M | -$2.6M | -$11.7M | -$57.4M |
| Impuestos | $1.2M | -$1.2M | -$3.7M | -$815000 | $518000 | $148000 | $337000 | $859000 | $740000 | -$686000 |
| Beneficio Neto | -$4.3M | -$865000 | -$3.5M | -$4.7M | -$7.8M | -$288000 | -$9.5M | -$3.4M | -$12.4M | -$56.7M |
| BPA | $-1.30 | $-0.26 | $-0.97 | $-1.20 | $-2.00 | $-0.07 | $-2.30 | $-0.81 | $-2.80 | $-12.80 |
| BPA Diluido | $-1.30 | $-0.25 | $-0.95 | $-1.20 | $-2.00 | $-0.07 | $-2.30 | $-0.81 | $-2.80 | $-12.80 |
| Acciones en Circulación (Diluidas) | $3.4M | $3.5M | $3.6M | $3.8M | $3.9M | $4.0M | $4.1M | $4.2M | $4.4M | $4.4M |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $5.6M | $5.7M | $8.2M | $8.3M | $8.3M | $7.8M | $4.5M | $4.3M | $4.1M | $8.6M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | $19.9M | $17.1M | $21.5M | $20.7M | $17.8M | $21.8M | $16.7M | $16.1M | $14.9M | $16.0M |
| Inventario | $20.0M | $21.4M | $25.1M | $22.1M | $22.3M | $27.6M | $26.4M | $24.7M | $23.2M | $20.8M |
| Activos Corrientes | $45.5M | $47.5M | $54.7M | $53.6M | $51.7M | $61.6M | $51.1M | $49.0M | $45.1M | $48.2M |
| Inmovilizado Material | $4.3M | $4.1M | $5.9M | $13.2M | $11.7M | $10.3M | $9.2M | $8.8M | $11.2M | $4.8M |
| Fondo de Comercio | $38.0M | $40.0M | $57.3M | $57.4M | $58.6M | $57.7M | $56.3M | $57.1M | $56.3M | $9.6M |
| Activos Intangibles | $18.7M | $17.2M | $45.8M | $38.4M | $33.2M | $27.4M | $21.0M | $16.0M | $11.1M | $7.6M |
| Activos Totales | $107.8M | $109.4M | $168.1M | $164.9M | $156.3M | $162.3M | $145.4M | $137.4M | $126.6M | $80.1M |
| Cuentas por Pagar | $6.2M | $4.4M | $7.4M | $5.3M | $6.0M | $4.9M | $6.4M | $5.6M | $4.8M | $3.7M |
| Deuda a Corto | $2.4M | $2.8M | $2.0M | $6.9M | $1.7M | $3.2M | $3.8M | $5.9M | $37.0M | $1.5M |
| Pasivos Corrientes | $14.6M | $14.0M | $21.5M | $25.3M | $21.1M | $25.3M | $23.2M | $26.5M | $55.0M | $22.0M |
| Deuda a Largo | $11.4M | $9.0M | $58.8M | $46.9M | $46.3M | $45.1M | $43.0M | $30.7M | 0 | $35.9M |
| Pasivos Totales | $35.6M | $28.5M | $85.9M | $83.2M | $79.6M | $78.9M | $73.1M | $64.3M | $63.3M | $66.3M |
| Reservas | -$116.0M | -$117.0M | -$119.9M | -$124.6M | -$132.4M | -$132.7M | -$142.2M | -$145.6M | -$158.0M | -$214.7M |
| Patrimonio Neto | $72.2M | $80.9M | $82.2M | $81.7M | $76.7M | $83.4M | $72.2M | $73.1M | $63.3M | $13.7M |
| Deuda Total | $13.7M | $11.7M | $60.8M | $64.5M | $57.6M | $57.0M | $54.2M | $42.8M | $44.5M | $44.3M |
| Deuda Neta | $8.2M | $6.0M | $52.6M | $56.1M | $49.3M | $49.1M | $49.7M | $38.5M | $40.4M | $35.7M |
| Capital Circulante | $30.9M | $33.5M | $33.2M | $28.3M | $30.6M | $36.3M | $27.9M | $22.5M | -$9.8M | $26.3M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$4.3M | -$865000 | -$3.5M | -$4.7M | -$7.8M | -$288000 | -$9.5M | -$3.4M | -$12.4M | -$56.7M |
| Amortizaciones | $4.3M | $3.8M | $7.9M | $7.7M | $7.6M | $7.6M | $7.6M | $7.0M | $7.2M | -$4.9M |
| Compensación en Acciones | $3.5M | $3.5M | $3.0M | $3.0M | $3.6M | $4.2M | $4.4M | $5.0M | $4.3M | -$1.7M |
| Cambio en Capital Circulante | -$41000 | -$3.8M | -$1.7M | $42000 | $4.1M | -$10.2M | $2.7M | $4.6M | $65000 | $5.7M |
| Flujo de Caja Operativo | $5.4M | $1.1M | $2.3M | $8.0M | $9.3M | $1.3M | $1.2M | $14.0M | $1.4M | $6.7M |
| Inversiones (CapEx) | -$1.5M | -$890000 | -$986000 | -$1.2M | -$1.2M | -$1.2M | -$1.6M | -$2.3M | -$3.3M | -$1.1M |
| Adquisiciones | $1.4M | $12000 | -$52.3M | $1.0M | 0 | 0 | 0 | $512000 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | -$221000 | -$1.1M | 0 | -$1.6M | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | $3.9M | $167000 | $1.4M | $6.8M | $8.2M | $67000 | -$438000 | $11.7M | -$1.8M | $5.6M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | -2.5% | +18.5% | -3.8% | -12.1% | +16.5% | -4.7% | -1.0% | -16.1% | -8.1% | |
| Crecimiento Beneficio Neto (anual) | +79.9% | -300.2% | -35.4% | -66.6% | +96.3% | -3204.2% | +64.1% | -263.3% | -357.1% | |
| Crecimiento BPA (anual) | +80.2% | -275.9% | -24.2% | -66.7% | +96.5% | -3139.4% | +65.0% | -247.8% | -357.1% | |
| Cambio en Acciones (anual) | +1.6% | +4.9% | +3.7% | +2.2% | +4.4% | +2.7% | +2.4% | +2.6% | +2.0% | |
| Crecimiento FCF (anual) | -95.7% | +713.2% | +403.0% | +19.7% | -99.2% | -753.7% | +2775.1% | -115.6% | +408.0% | |
| Margen Bruto | 46.3% | 46.7% | 52.3% | 55.4% | 56.8% | 56.9% | 53.7% | 58.9% | 58.2% | 53.0% |
| Margen Operativo | -2.9% | -0.1% | 0.8% | 0.3% | 0.2% | 1.7% | -6.1% | 1.7% | -6.6% | -0.7% |
| Margen EBITDA | 1.7% | -0.1% | 4.4% | 6.6% | 5.1% | 7.6% | 0.8% | 7.2% | -1.6% | -53.8% |
| Margen Neto | -4.1% | -0.8% | -2.9% | -4.0% | -7.6% | -0.2% | -8.4% | -3.0% | -13.2% | -65.5% |
| Margen FCF | 3.7% | 0.2% | 1.1% | 5.9% | 8.0% | 0.1% | -0.4% | 10.4% | -1.9% | 6.5% |
| Tasa Impositiva Efectiva | -39.9% | 58.6% | 43.2% | 14.8% | -7.1% | -105.7% | -3.7% | -33.6% | -6.3% | 1.2% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $1.14 | $0.05 | $0.37 | $1.81 | $2.12 | $0.02 | $-0.11 | $2.76 | $-0.42 | $1.26 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $3.4M | $3.4M | $3.6M | $3.8M | $3.9M | $4.0M | $4.1M | $4.2M | $4.4M | $4.4M |
Qué mirar en Salud / Farma
El pipeline de I+D es el activo invisible. Patentes que caducan = ingresos que evaporan. Mira innovación y flujo de caja.
- I+D / Ingresos — Indica inversión en pipeline futuro. Farma seria reinvierte 15-20%
- Crecimiento EPS 5y — Tras caducidad de patentes, ¿siguen creciendo?
- Margen bruto — Farma de marca >70%. Genéricos mucho más bajo — define el tipo de negocio
- FCF / Net Income — Calidad del beneficio — farma grande debería convertir >90%
- ROIC — Capital reinvertido con eficiencia — clave en farma por ciclos de I+D largos
- Deuda neta / EBITDA — Adquisiciones de farma generan mucha deuda — ojo al post-M&A
- P/E vs historial 10y propio — La mejor comparación es con su propia historia, no con competidores
Rentabilidad
| Rentabilidad sobre capital | -92.01% |
| Rentabilidad sobre capital invertido | 1.91% |
| Rentabilidad sobre activos | -13.65% |
| Margen bruto | 58.16% |
| Margen operativo | 1.17% |
| Margen neto | -11.86% |
Salud financiera
| Deuda / Patrimonio | 5.96 |
| Ratio corriente | 1.87 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.04 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -23.46 | -128.40 | -32.92 | -25.42 | -21.45 | -992.96 | -12.04 | -66.46 | -7.54 | -0.52 |
| P/VC | 1.45 | 1.37 | 1.39 | 1.41 | 2.16 | 3.41 | 1.59 | 3.11 | 1.45 | 2.16 |
| P/V | 1.00 | 1.09 | 0.94 | 0.99 | 1.62 | 2.39 | 1.01 | 2.02 | 0.98 | 0.34 |
| Margen Bruto | 46.3% | 46.7% | 52.3% | 55.4% | 56.8% | 56.9% | 53.7% | 58.9% | 58.2% | 53.0% |
| Margen Operativo | -2.9% | -0.1% | 0.8% | 0.3% | 0.2% | 1.7% | -6.1% | 1.7% | -6.6% | -0.7% |
| Margen Neto | -4.1% | -0.8% | -2.9% | -4.0% | -7.6% | -0.2% | -8.4% | -3.0% | -13.2% | -65.5% |
Empresas relacionadas: CLGN · COSM · FEMY · NCNA · NXGL · NXL · RVP
Explorar sector: Healthcare · Medical - Instruments & Supplies
Más secciones de HBIO: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones